CO2020014217A2 - Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos - Google Patents

Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos

Info

Publication number
CO2020014217A2
CO2020014217A2 CONC2020/0014217A CO2020014217A CO2020014217A2 CO 2020014217 A2 CO2020014217 A2 CO 2020014217A2 CO 2020014217 A CO2020014217 A CO 2020014217A CO 2020014217 A2 CO2020014217 A2 CO 2020014217A2
Authority
CO
Colombia
Prior art keywords
compositions
methyl modifying
modifying enzyme
enzyme modulators
methyl
Prior art date
Application number
CONC2020/0014217A
Other languages
English (en)
Inventor
Alexandre Côté
Victor S Gehling
Avinash Khanna
Ludivine Moine
Jacob I Stuckey
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CO2020014217A2 publication Critical patent/CO2020014217A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos compuestos de Fórmula (I): (I); y sales farmacéuticamente aceptables de estos, que son útiles para tratar una variedad de enfermedades, trastornos o afecciones asociadas con enzimas modificadoras de metilo. También se proporcionan composiciones farmacéuticas que comprenden los nuevos compuestos de Fórmula (I), sales farmacéuticamente aceptables de estos y métodos para su uso en el tratamiento de una o más enfermedades, trastornos o afecciones, asociados con enzimas modificadoras de metilo.
CONC2020/0014217A 2018-04-18 2020-11-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos CO2020014217A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
PCT/US2019/027932 WO2019204490A1 (en) 2018-04-18 2019-04-17 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
CO2020014217A2 true CO2020014217A2 (es) 2021-03-08

Family

ID=66429588

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0014217A CO2020014217A2 (es) 2018-04-18 2020-11-17 Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos

Country Status (22)

Country Link
US (3) US10689371B2 (es)
EP (1) EP3781561B1 (es)
JP (2) JP7256823B2 (es)
KR (1) KR20210003160A (es)
CN (1) CN111989325A (es)
AR (1) AR114793A1 (es)
AU (1) AU2019255310B2 (es)
BR (1) BR112020021194A2 (es)
CA (1) CA3098428A1 (es)
CL (1) CL2020002698A1 (es)
CO (1) CO2020014217A2 (es)
CR (1) CR20200553A (es)
EA (1) EA202092490A1 (es)
IL (1) IL278013B2 (es)
MA (1) MA52288A (es)
MX (1) MX2020010999A (es)
PE (1) PE20201448A1 (es)
PH (1) PH12020551578A1 (es)
SG (1) SG11202009438UA (es)
TW (1) TWI828677B (es)
UA (1) UA127357C2 (es)
WO (1) WO2019204490A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111989325A (zh) 2018-04-18 2020-11-24 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2020316073A1 (en) * 2019-07-24 2022-02-17 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d] [1,3]dioxole-5-carboxamide
JP2022541633A (ja) * 2019-07-24 2022-09-26 コンステレーション・ファーマシューティカルズ・インコーポレイテッド がんの治療のためのｅｚｈ２阻害併用療法
TW202144341A (zh) * 2020-03-13 2021-12-01 大陸商四川海思科製藥有限公司 Zeste同源基因增強子2抑制劑及其用途
IL299730A (en) * 2020-07-08 2023-03-01 Daiichi Sankyo Co Ltd Production method of 1,3-benzodioxole derivative
EP4247371A1 (en) * 2020-11-18 2023-09-27 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of androgen receptor mutated prostate cancers
KR20220101295A (ko) 2021-01-11 2022-07-19 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
WO2023135564A1 (ko) * 2022-01-14 2023-07-20 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
IL92544A0 (en) 1988-12-08 1990-08-31 Duphar Int Res Piperazine derivatives,their preparation and pharmaceutical compositions containing them
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
WO1997026884A1 (en) 1996-01-29 1997-07-31 The Regents Of The University Of California Method for treating sexual dysfunctions
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
AU745641B2 (en) 1997-10-27 2002-03-28 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
CA2344169C (en) 1998-09-29 2011-07-19 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
MXPA03001332A (es) 2000-08-21 2004-07-08 Astrazeneca Ab Derivados de quinazolina.
WO2002016327A1 (en) 2000-08-23 2002-02-28 The Procter & Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
ES2395721T3 (es) 2000-08-24 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivados de tioflavina y su uso en diagnosis y terapia de la enfermedad de alzheimer
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
CA2470427C (en) 2001-12-21 2012-07-10 Cytokinetics, Incorporated Compositions and methods for treating heart failure
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CZ20041015A3 (cs) 2002-04-09 2005-01-12 Novogen Research Pty Ltd Terapeutické způsoby a prostředeky zahrnující isoflav-3-enové a isoflavanové struktury
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
CA2499602A1 (en) 2002-09-23 2004-04-01 Graham Edmund Kelly Skin photoageing and actinic damage treatment
WO2005011686A1 (en) 2003-07-28 2005-02-10 Applied Research Systems Ars Holding N.V. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
WO2005030704A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
EP1685140A4 (en) 2003-11-18 2009-02-25 Novogen Res Pty Ltd PRODRUGS BASED ON ISOFLAVONOIDS, COMPOSITIONS THEREOF AND THERAPEUTIC PROCESSES INVOLVING THEM
CN101123958A (zh) 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
RU2006127414A (ru) 2004-01-16 2008-02-27 Вайет (Us) Хинолиновые промежуточные соединения ингибиторов рецептора тирозинкиназы и их синтез
WO2005100321A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005293556A1 (en) 2004-10-12 2006-04-20 Merck Serono Sa PI3 Kinase gamma inhibitors for the treatment of anaemia
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
DK1859793T3 (da) 2005-02-28 2011-08-01 Eisai R&D Man Co Ltd Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer
WO2006096807A1 (en) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
US20090286785A1 (en) 2005-04-08 2009-11-19 Bayer Pharmaceuticals Corporation Pyrimidine Derivatives
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
CA2608394A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
JPWO2006129609A1 (ja) 2005-05-30 2009-01-08 塩野義製薬株式会社 ２−ナフチルイミノ−５，５−ジ置換−１，３−チアジン誘導体
CN101208088A (zh) 2005-06-02 2008-06-25 拜尔农作物科学股份公司 苯基烷基取代的杂芳基衍生物
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1910273A2 (en) 2005-07-21 2008-04-16 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
JP5066088B2 (ja) 2005-08-04 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ セロトニン受容体モジュレーターとしてのピリミジン化合物
EP1932837A4 (en) 2005-08-17 2011-05-25 Daiichi Sankyo Co Ltd HETEROCYCLIC BICYCLOUS BINDING WITH ANTIPILY EFFECT
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
ATE518564T1 (de) 2006-03-23 2011-08-15 Biota Europe Ltd Benzamide- und pyridylamide-derivate als antibakterielle mittel
ZA200807756B (en) 2006-05-30 2009-11-25 Neurosearch As Novel 1,4-diaza-bicyclo[3.2.2] nonyl oxadiazolyl derivatives and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2084141A4 (en) 2006-10-30 2010-07-21 Novogen Res Pty Ltd PREVENTION AND REVERSION OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
EP2146722A4 (en) 2007-05-10 2011-08-03 Amr Technology Inc ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
VN29259A1 (en) 2008-04-16 2012-04-25 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8188287B2 (en) 2008-06-23 2012-05-29 Janssen Pharmaceutica N.V. Piperidyl acrylamide antagonists of CCR2
WO2010019772A2 (en) 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
AR076928A1 (es) 2009-05-28 2011-07-20 Otsuka Pharma Co Ltd Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres.
JP2012532850A (ja) 2009-07-10 2012-12-20 ビバリス Ｃ型肝炎ｎｓ５ｂポリメラーゼの阻害剤としての置換ピロリジノン、その医薬組成物、およびそれらの治療上の使用
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
CN102762703B (zh) 2009-12-17 2016-12-07 路博润公司 含芳族化合物的润滑组合物
JP5833022B2 (ja) 2010-01-27 2015-12-16 エービー・ファーマ・リミテッド Ｃ型肝炎ウィルス阻害剤としてのポリ複素環式化合物
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
WO2012013725A1 (en) 2010-07-28 2012-02-02 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2774917A4 (en) 2011-11-04 2015-05-06 Ajinomoto Kk PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
BR112015004284A2 (pt) 2012-08-30 2017-07-04 Nippon Shinyaku Co Ltd derivado de piridina e medicina
AU2013334707B2 (en) 2012-10-22 2018-02-22 City Of Hope ETP derivatives
AU2014243869A1 (en) 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US20160108031A1 (en) 2013-04-30 2016-04-21 Heinrich-Heine-Universitat Dusseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
CA2923522C (en) 2013-09-09 2018-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
KR102302830B1 (ko) * 2014-03-17 2021-09-15 다이이찌 산쿄 가부시키가이샤 1,3-벤조디옥솔 유도체
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
WO2016038540A1 (en) 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
US20180037568A1 (en) * 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2828961T3 (es) 2015-07-30 2021-05-28 Daiichi Sankyo Co Ltd Agente terapéutico y/o profiláctico para leucemia/linfoma de células T del adulto
US10759787B2 (en) 2015-11-19 2020-09-01 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
MX2018008644A (es) 2016-01-13 2018-11-19 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
CA3012133A1 (en) 2016-02-09 2017-08-17 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (ido)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
CN110191722B (zh) 2017-01-19 2022-03-01 第一三共株式会社 用于治疗htlv-1相关性脊髓病的药物组合物
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
US20210177827A1 (en) 2017-10-25 2021-06-17 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
US20210177781A9 (en) 2018-01-12 2021-06-17 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (en) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
CN111989325A (zh) 2018-04-18 2020-11-24 星座制药公司 甲基修饰酶的调节剂、其组合物和用途

Also Published As

Publication number Publication date
SG11202009438UA (en) 2020-11-27
TWI828677B (zh) 2024-01-11
AU2019255310A1 (en) 2020-10-15
AR114793A1 (es) 2020-10-14
EA202092490A1 (ru) 2020-12-23
IL278013A (en) 2020-11-30
CA3098428A1 (en) 2019-10-24
TW202003505A (zh) 2020-01-16
US20190322651A1 (en) 2019-10-24
JP2021522166A (ja) 2021-08-30
PE20201448A1 (es) 2020-12-10
US11274095B2 (en) 2022-03-15
MX2020010999A (es) 2021-01-20
EP3781561A1 (en) 2021-02-24
UA127357C2 (uk) 2023-07-26
BR112020021194A2 (pt) 2021-03-23
JP7256823B2 (ja) 2023-04-12
CR20200553A (es) 2021-04-08
MA52288A (fr) 2021-04-07
IL278013B1 (en) 2023-09-01
US20200317651A1 (en) 2020-10-08
CN111989325A (zh) 2020-11-24
PH12020551578A1 (en) 2021-09-13
IL278013B2 (en) 2024-01-01
CL2020002698A1 (es) 2021-01-15
KR20210003160A (ko) 2021-01-11
WO2019204490A1 (en) 2019-10-24
US10689371B2 (en) 2020-06-23
EP3781561B1 (en) 2024-03-13
AU2019255310B2 (en) 2022-11-24
JP2023082132A (ja) 2023-06-13
US20240116905A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
NI202000078A (es) Compuestos heteroaril tetracíclicos
UY37098A (es) Moduladores de ror-gamma
ECSP19048759A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
CO2021008816A2 (es) Moduladores de trex1
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2020012359A2 (es) Moduladores calpaína y usos terapéuticos de los mismos
CR20190379A (es) Moduladores del receptor de estrógeno
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
DOP2011000053A (es) Agentes antifungicos
ECSP23088732A (es) Moduladores de trex1
UY37551A (es) Activador de nrf2
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ECSP18056196A (es) Derivados de indano
CO2021010512A2 (es) Compuesto heterociclo pentacíclico
AR102887A1 (es) Una triazolopiridazina como modulador de quinasa